Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data
Compared to single-drug therapy, combination therapy involves the use of two or more drugs to reduce drug dosage, decrease drug toxicity, and improve treatment efficacy. We developed an extreme gradient boosting (XGBoost)-based drug-drug cell line prediction model (XDDC) to predict synergistic drug...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2025-02-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/19078.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229017337135104 |
|---|---|
| author | Jiaqi Chen Huirui Han Lingxu Li Zhengxin Chen Xinying Liu Tianyi Li Xuefeng Wang Qibin Wang Ruijie Zhang Dehua Feng Lei Yu Xia Li Limei Wang Bing Li Jin Li |
| author_facet | Jiaqi Chen Huirui Han Lingxu Li Zhengxin Chen Xinying Liu Tianyi Li Xuefeng Wang Qibin Wang Ruijie Zhang Dehua Feng Lei Yu Xia Li Limei Wang Bing Li Jin Li |
| author_sort | Jiaqi Chen |
| collection | DOAJ |
| description | Compared to single-drug therapy, combination therapy involves the use of two or more drugs to reduce drug dosage, decrease drug toxicity, and improve treatment efficacy. We developed an extreme gradient boosting (XGBoost)-based drug-drug cell line prediction model (XDDC) to predict synergistic drug combinations. XDDC was based on XGBoost and used one of the largest drug combination datasets, NCI-ALMANAC. In XDDC, drug chemical structures, adverse drug reactions, and target information were selected as drug features; gene expression, methylation, mutations, copy number variations, and RNA interference data were used as cell line features; and pathway information was incorporated to link drug features and cell line features. XDDC improved the interpretability of drug combination features and outperformed other machine learning methods. It achieved an area under the curve (AUC) of 0.966 ± 0.002 and an AUPR of 0.957 ± 0.002 when cross-validated on NCI-ALMANAC data. Different types of omics data were evaluated and compared in the model. Literature and experimental verification confirmed some of our predictions. XDDC could help medical professionals to rapidly screen synergistic drug combinations against specific cancer cell lines. |
| format | Article |
| id | doaj-art-2e9a58be8cea48369d254b382eb43423 |
| institution | OA Journals |
| issn | 2167-8359 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj-art-2e9a58be8cea48369d254b382eb434232025-08-20T02:04:21ZengPeerJ Inc.PeerJ2167-83592025-02-0113e1907810.7717/peerj.19078Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics dataJiaqi ChenHuirui HanLingxu LiZhengxin ChenXinying LiuTianyi LiXuefeng WangQibin WangRuijie ZhangDehua FengLei YuXia LiLimei WangBing LiJin LiCompared to single-drug therapy, combination therapy involves the use of two or more drugs to reduce drug dosage, decrease drug toxicity, and improve treatment efficacy. We developed an extreme gradient boosting (XGBoost)-based drug-drug cell line prediction model (XDDC) to predict synergistic drug combinations. XDDC was based on XGBoost and used one of the largest drug combination datasets, NCI-ALMANAC. In XDDC, drug chemical structures, adverse drug reactions, and target information were selected as drug features; gene expression, methylation, mutations, copy number variations, and RNA interference data were used as cell line features; and pathway information was incorporated to link drug features and cell line features. XDDC improved the interpretability of drug combination features and outperformed other machine learning methods. It achieved an area under the curve (AUC) of 0.966 ± 0.002 and an AUPR of 0.957 ± 0.002 when cross-validated on NCI-ALMANAC data. Different types of omics data were evaluated and compared in the model. Literature and experimental verification confirmed some of our predictions. XDDC could help medical professionals to rapidly screen synergistic drug combinations against specific cancer cell lines.https://peerj.com/articles/19078.pdfDrug synergy predictionMulti-omicsMachine learningCancerDrug combination |
| spellingShingle | Jiaqi Chen Huirui Han Lingxu Li Zhengxin Chen Xinying Liu Tianyi Li Xuefeng Wang Qibin Wang Ruijie Zhang Dehua Feng Lei Yu Xia Li Limei Wang Bing Li Jin Li Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data PeerJ Drug synergy prediction Multi-omics Machine learning Cancer Drug combination |
| title | Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data |
| title_full | Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data |
| title_fullStr | Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data |
| title_full_unstemmed | Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data |
| title_short | Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data |
| title_sort | prediction of cancer cell line specific synergistic drug combinations based on multi omics data |
| topic | Drug synergy prediction Multi-omics Machine learning Cancer Drug combination |
| url | https://peerj.com/articles/19078.pdf |
| work_keys_str_mv | AT jiaqichen predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT huiruihan predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT lingxuli predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT zhengxinchen predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT xinyingliu predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT tianyili predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT xuefengwang predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT qibinwang predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT ruijiezhang predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT dehuafeng predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT leiyu predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT xiali predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT limeiwang predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT bingli predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata AT jinli predictionofcancercelllinespecificsynergisticdrugcombinationsbasedonmultiomicsdata |